Abstract:Mechanical loading up‐regulates the expression of PGE2, which binds to EP2 to inhibit TGFβ signalling through a CYLD‐dependent proteasome mechanism, thereby inhibiting the transactivation of pSmad2/3 and subsequently inhibiting the expression of Sost. The phosphorylation of USP4 by Ck2 can also inhibit the transcription of Sost by inhibiting ubiquitination degradation of SIRT1. Sost then acts as an antagonist of WNT/β‐catenin signalling and a promoter of RANK/RANKL signalling to modulate bone remodelling. In addition, USP53 is involved in the regulation of osteoblast–osteoclast coupling. Mechanistically, USP53 inhibits the interaction between Smad3 and VDR in osteoblasts, resulting in reduced binding of VDR to its cognate elements, thereby inhibiting the activation of RANKL. Osteoporosis is an ageing‐related disease, that has become a major public health problem and its pathogenesis has not yet been fully elucidated. Substantial evidence suggests a strong link between overall age‐related disease progression and epigenetic modifications throughout the life cycle. As an important epigenetic modification, ubiquitination is extensively involved in various physiological processes, and its role in bone metabolism has attracted increasing attention. Ubiquitination can be reversed by deubiquitinases, which counteract protein ubiquitination degradation. As the largest and most structurally diverse cysteinase family of deubiquitinating enzymes, ubiquitin‐specific proteases (USPs), comprising the largest and most structurally diverse cysteine kinase family of deubiquitinating enzymes, have been found to be important players in maintaining the balance between bone formation and resorption. The aim of this review is to explore recent findings highlighting the regulatory functions of USPs in bone metabolism and provide insight into the molecular mechanisms governing their actions during bone loss. An in‐deep understanding of USPs‐mediated regulation of bone formation and bone resorption will provide a scientific rationale for the discovery and development of novel USP‐targeted therapeutic strategies for osteoporosis.

E3 Ubiquitin Ligase-Mediated Regulation of Osteoblast Differentiation and Bone Formation

Wnt Signaling:Essential Roles in Osteoblast Differentiation,bone Metabolism and Therapeutic Implications for Bone and Skeletal Disorders

Tgf-Beta and Bmp Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease

C/Ebp Alpha Regulates Osteoclast Lineage Commitment

The Regulation of E3 Ubiquitin Ligases Cbl and its Cross-talking in Bone Homeostasis

The Deubiquitinase UCHL1 Negatively Controls Osteoclastogenesis by Regulating TAZ/NFATC1 Signalling

Ubiquitin-specific proteases: Vital regulatory molecules in bone and bone-related diseases

Ubiquitin‐specific peptidases: Players in bone metabolism

The Role of E3 Ubiquitin Ligase Smurfs in Bmp and Tgf-Bata Signaling in Bone Cells

E3-ubiquitin ligases and recent progress in osteoimmunology

E3 Ubiquitin Ligases: Key Regulators of TGFβ Signaling in Cancer Progression

NEDD4 E3 Ligases: Functions and Mechanisms in Bone and Tooth

Deubiquitinating Enzymes and Bone Remodeling

USP36 regulates the proliferation, survival, and differentiation of hFOB1.19 osteoblast

Elucidating the role of ubiquitination and deubiquitination in osteoarthritis progression

E3 Ubiquitin Ligases in Cancer and Implications for Therapies

E3 Ubiquitin Ligases: Key Regulators of TGF Signaling in Cancer Progression

E3 ubiquitin ligase on the biological properties of hematopoietic stem cell

The Role of Deubiquitinating Enzymes in Primary Bone Cancer

The osteoprotective role of USP26 in coordinating bone formation and resorption

TGF‐β Inhibits Osteogenesis by Upregulating the Expression of Ubiquitin Ligase SMURF1 Via MAPK‐ERK Signaling